Stay updated on Alvocidib Biomarker AML Phase 2 Clinical Trial
Sign up to get notified when there's something new on the Alvocidib Biomarker AML Phase 2 Clinical Trial page.

Latest updates to the Alvocidib Biomarker AML Phase 2 Clinical Trial page
- CheckyesterdayChange DetectedThe page now displays Revision: v3.5.4, updating the site revision from the previous v3.5.3. This indicates a software/version update rather than a change to the study data or layout.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedRevision changed from v3.5.2 to v3.5.3 on the page, indicating a deployed update to the study entry. This version bump does not modify the study information presented to users.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check30 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. No visible changes to study data, eligibility criteria, or page navigation.SummaryDifference0.0%

- Check51 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check65 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check94 days agoChange DetectedAdded Revision: v3.4.2; removed the lapse-in-funding notice and Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Alvocidib Biomarker AML Phase 2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Alvocidib Biomarker AML Phase 2 Clinical Trial page.